The double downgrade from Citigroup adds to a growing bearish consensus, but with the stock already pricing in significant downside via 57.7% short interest, the incremental negative surprise is limited. The real risk is a short squeeze if upcoming earnings on Nov 6 surprise to the upside, given the upward EPS revision trend.
MRNA drugs
MRNA drug pipeline →Price Chart
Executive Summary
Citigroup double-downgraded Moderna (MRNA) from Neutral to Sell on September 30, 2026, while raising its price target from $60 to $80. The new target implies a 60.7% downside from the current price of $203.46. Citigroup's accuracy on MRNA is 50% based on 2 scored calls, with an average return of 31.7%, placing it below average among covering firms. The consensus on MRNA is heavily skewed toward Hold, with 17 of 30 analysts at Hold, 11 at Buy/Strong Buy, and 2 at Sell/Strong Sell. The mean price target is $119.56, and the median is $125, with a high of $170 and a low of $45. Citigroup's $80 target is well below the mean and median, making it one of the most bearish on the Street. Over the past 30 days, MRNA has seen 2 downgrades and 0 upgrades, with EPS revisions trending higher, 7 upward revisions vs 1 downward for the current fiscal year. Insider selling has been heavy, with over $11.6 million in sales by the CFO and other executives in September. Short interest stands at 57.7% of float, reflecting extreme bearish positioning. The next earnings report is due November 6, 2026, adding a near-term catalyst. This double downgrade from a below-average-accuracy firm, while directionally bearish, is largely aligned with consensus caution and existing short interest, limiting its incremental impact.
Impact Score
Consensus & Targets
The consensus is 36.7% Buy (4 Strong Buy, 7 Buy), 56.7% Hold (17 Hold), and 6.7% Sell (2 Sell, 0 Strong Sell) based on 30 analysts. The consensus is heavily tilted toward Hold, reflecting broad caution but not outright bearishness. Citigroup's Sell call places it in the minority bearish camp.
The mean price target is $119.56, median $125, high $170, low $45. At $203.46, MRNA trades 70.2% above the mean target. Citigroup's $80 target is 33.1% below the mean and 36% below the median, making it the second-lowest target after the $45 low. The implied downside to Citigroup's target is 60.7%.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-09-30 | Citigroup | downgrade | Sell | $80.00 |
| 2026-09-03 | Rothschild & Co | downgrade | Sell | $81.00 |
| 2026-08-28 | Argus Research | upgrade | Buy | No target |
| 2026-08-25 | Wolfe Research | upgrade | Peer Perform | No target |
| 2026-08-24 | Barclays | maintain | Equal-Weight | $125.00 |
| 2026-08-21 | JP Morgan | maintain | Underweight | $77.00 |
| 2026-08-20 | Goldman Sachs | maintain | Neutral | $120.00 |
| 2026-08-20 | UBS | maintain | Neutral | $150.00 |
| 2026-08-20 | Morgan Stanley | maintain | Equal-Weight | $89.00 |
| 2026-08-19 | William Blair | upgrade | Outperform | No target |
Over the past 30 days, MRNA has received 0 upgrades and 2 downgrades (Citigroup and Rothschild & Co). EPS revisions are trending higher: 7 upward revisions vs 1 downward for the current fiscal year, and 6 up vs 4 down for next year. The current-year EPS estimate improved from -$8.54 to -$8.38 over the past 30 days. Despite the bearish analyst actions, earnings estimates are being revised higher.
Firm Track Record: Citigroup
Citigroup accuracy: 54% on 4902 calls | avg return: 4.7%
Industry benchmark: mean 51% ± 10%. Top tier: ≥61% (mean + 1σ). Based on 13 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Jefferies | 100% | 2/2 | 42.6% | top tier |
| Morgan Stanley | 75% | 3/4 | 26.9% | top tier |
| B of A Securities | 67% | 2/3 | 10% | top tier |
| Leerink Partners | 50% | 1/2 | 48.9% | below average |
| Citigroup | 50% | 1/2 | 31.7% | below average |
| JP Morgan | 50% | 3/6 | -7.9% | below average |
| RBC Capital | 38% | 3/8 | -7.9% | below average |
| Needham | 38% | 3/8 | -14.3% | below average |
| Barclays | 33% | 2/6 | -7.5% | below average |
| Piper Sandler | 25% | 1/4 | 4.5% | below average |
Citigroup has a 50% accuracy rate on 2 scored calls for MRNA, with an average return of 31.7%, classified as below average. Among covering firms, Jefferies (100% on 2 calls, +42.6% avg return) and Morgan Stanley (75% on 4 calls, +26.9% avg return) are top-tier. Oppenheimer (0% on 2 calls, -41.8% avg return) and Evercore ISI (0% on 4 calls, -29.1% avg return) are the worst performers.
Earnings Estimates
Next earnings: Nov 6, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $-1.29 | $-3.32 to $-0.53 | $895.0M | ↑2 ↓0 |
| +1q | $-1.74 | $-2.09 to $-0.63 | $667.8M | ↑3 ↓0 |
| 0y | $-8.38 | $-10.55 to $-6.66 | $2.1B | ↑3 ↓0 |
| +1y | $-4.79 | $-7.11 to $-2.73 | $2.4B | ↑2 ↓0 |
Cross-Platform Signals
Insider selling is heavy and concentrated: CFO Stephen Hoge sold $11.7 million on Sep 14-15, and EVP James Mock sold $4.7 million on Sep 10. These are large, non-routine sales that align with the bearish analyst signal. Congressional activity is mixed, Rep. Maria Elvira Salazar made both a buy and a sell in the $1k-$15k range on Aug 19. Institutional activity is mixed: Citadel trimmed 39.9%, JPMorgan trimmed 36.4%, while Bank of America added 42.9% and American Century added 44.6%. Short interest is extremely high at 57.7% of float, indicating crowded bearish positioning. The convergence of heavy insider selling, institutional trimming by major funds, and extreme short interest amplifies the bearish signal from the downgrade.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
26 reports on MRNA
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 Viewing No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers